{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:03:34Z","timestamp":1758931414039,"version":"3.44.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to investigate the impact of gut microbiota intervention on the therapeutic outcomes in patients with drug-induced liver injury (DILI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 120 patients with DILI who were hospitalized at the Second Hospital of Lanzhou University from January 2023 to December 2024 were retrospectively enrolled. Patients were divided into an intervention group and a control group based on whether they received gut microbiota intervention therapy. Quantitative data were presented as median and interquartile range, and the Mann\u2013Whitney U test was used for intergroup comparisons. Categorical variables were compared between groups using chi-square tests. Logistic regression analysis was used to identify factors associated with liver injury severity and to evaluate the effect of gut microbiota intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After treatment, GGT, ALP, TBIL, DBIL and IBIL decreased significantly more in the intervention group than in the control group, and the differences were statistically significant (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.01). Before treatment, the intervention group had a higher proportion of patients with grade 1 and grade 4 DILI, while the control group had more patients with grade 2 and grade 3 DILI. After treatment, the proportion of grade 1 patients in the intervention group increased significantly, whereas the proportion of grade 4 patients decreased markedly. These changes were statistically significant between the two groups (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.01). Logistic regression analysis showed that the risk of liver injury was significantly reduced in the intervention group after treatment (OR\u202f=\u202f0.018, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.01). In terms of model prediction accuracy, the prediction rate for moderate liver injury was relatively high (91.0%), whereas the accuracy for acute liver failure and severe liver injury was lower. The overall prediction accuracy of the model was 75.0%. Pearson correlation analysis revealed that post-treatment DILI grade was significantly associated with treatment regimen, TBIL, ALP and GGT (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Probiotic intervention significantly improved cholestasis-related parameters and reduced the severity of liver injury in patients with DILI. This real-world study provides novel clinical evidence supporting microbiota-targeted therapy as a promising adjunctive strategy, particularly for cholestasis-predominant DILI.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnut.2025.1657629","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:12:05Z","timestamp":1758859925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Probiotic intervention improves cholestatic parameters in patients with drug-induced liver injury: a real-world retrospective study"],"prefix":"10.3389","volume":"12","author":[{"given":"Na","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jizhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyuan","family":"Mou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/10937404.2023.2261848","article-title":"Drug induced liver injury - a 2023 update","volume":"26","author":"Allison","year":"2023","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12072-023-10633-7","article-title":"Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update","volume":"18","author":"Mao","year":"2024","journal-title":"Hepatol Int"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejim.2021.10.035","article-title":"Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management","volume":"97","author":"Bj\u00f6rnsson","year":"2022","journal-title":"Eur J Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"126707","DOI":"10.1016\/j.jhazmat.2021.126707","article-title":"Gut microbiota exaggerates triclosan-induced liver injury via gut-liver axis","volume":"421","author":"Zhang","year":"2022","journal-title":"J Hazard Mater"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","article-title":"Contribution of the intestinal microbiome and gut barrier to hepatic disorders","volume":"159","author":"Chopyk","year":"2020","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41575-018-0099-1","article-title":"Alcohol, liver disease and the gut microbiota","volume":"16","author":"Bajaj","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"101355","DOI":"10.1016\/j.jcmgh.2024.05.003","article-title":"Interplay between drug-induced liver injury and gut microbiota: a comprehensive overview","volume":"18","author":"Li","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmgh.2020.11.002","article-title":"Intestinal dysbiosis amplifies acetaminophen-induced acute liver injury","volume":"11","author":"Schneider","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1155306","DOI":"10.3389\/fnut.2023.1155306","article-title":"Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials","volume":"10","author":"Cao","year":"2023","journal-title":"Front Nutr"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e2200986","DOI":"10.1002\/advs.202200986","article-title":"Hierarchy-assembled dual probiotics system ameliorates cholestatic drug-induced liver injury via gut-liver Axis modulation","volume":"9","author":"Chen","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1432049","DOI":"10.3389\/fmicb.2024.1432049","article-title":"Gut microbiota causally affects drug-induced liver injury via plasma metabolites: a mendelian randomization study","volume":"15","author":"Fu","year":"2024","journal-title":"Front Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"972518","DOI":"10.3389\/fmed.2022.972518","article-title":"Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf causality assessment method: emerging role of gut microbiota dysbiosis","volume":"9","author":"Fu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s11655-020-3268-3","article-title":"Intestinal microecology: an important target for Chinese medicine treatment of non-alcoholic fatty liver disease","volume":"26","author":"Li","year":"2020","journal-title":"Chin J Integr Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.3390\/molecules29112663","article-title":"Role of gut microecology in the pathogenesis of drug-induced liver injury and emerging therapeutic strategies","volume":"29","author":"Huang","year":"2024","journal-title":"Molecules"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e17878","DOI":"10.1016\/j.heliyon.2023.e17878","article-title":"Bifidobacterium lactis TY-S01 protects against alcoholic liver injury in mice by regulating intestinal barrier function and gut microbiota","volume":"9","author":"Shu","year":"2023","journal-title":"Heliyon"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/hep.30975","article-title":"Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.hbpd.2023.06.008","article-title":"Contribution of gut microbiota to drug-induced liver injury","volume":"22","author":"Chu","year":"2023","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","article-title":"The gut-liver axis and gut microbiota in health and liver disease","volume":"21","author":"Hsu","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.3390\/foods13182992","article-title":"Probiotics and non-alcoholic fatty liver disease: unveiling the mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in modulating lipid metabolism, inflammation, and intestinal barrier integrity","volume":"13","author":"Lu","year":"2024","journal-title":"Foods"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"586392","DOI":"10.3389\/fcimb.2021.586392","article-title":"The impact of gut microbiota on radiation-induced enteritis","volume":"11","author":"Jian","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1254198","DOI":"10.3389\/fcimb.2023.1254198","article-title":"Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms","volume":"13","author":"Peng","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2291164","DOI":"10.1080\/19490976.2023.2291164","article-title":"Bifidobacterium mechanisms of immune modulation and tolerance","volume":"15","author":"Gavzy","year":"2023","journal-title":"Gut Microbes"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.canlet.2021.11.027","article-title":"Gut microbiota-derived short-chain fatty acids and colorectal cancer: ready for clinical translation?","volume":"526","author":"Hou","year":"2022","journal-title":"Cancer Lett"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"844242","DOI":"10.3389\/fnut.2022.844242","article-title":"Effect of probiotics on liver enzymes in patients with non-alcoholic fatty liver disease: an umbrella of systematic review and Meta-analysis","volume":"9","author":"Musazadeh","year":"2022","journal-title":"Front Nutr"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"11397","DOI":"10.1021\/acs.jmedchem.0c00524","article-title":"Drug induced liver injury (DILI). Mechanisms and medicinal chemistry avoidance\/mitigation strategies","volume":"63","author":"Norman","year":"2020","journal-title":"J Med Chem"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.3390\/ijms23137229","article-title":"The activity of prebiotics and probiotics in Hepatogastrointestinal disorders and diseases associated with metabolic syndrome","volume":"23","author":"Rodr\u00edguez-Past\u00e9n","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1657629\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:12:05Z","timestamp":1758859925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1657629\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":26,"alternative-id":["10.3389\/fnut.2025.1657629"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2025.1657629","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"article-number":"1657629"}}